Eledon Pharmaceuticals Inc at NobleCon Investor Conference (Virtual) Transcript
Good morning, everyone, and thank you to the team at Noble for inviting us to present today.
Before we begin, I'd like to remind you that statements made during this presentation relating to Eledon's expected future performance or plans may include forward-looking statements that are intended to be subject to Safe Harbor protection. Please review both the slide for details, as well as our risk factors in our publicly filed SEC documents.
I'm pleased to present today with Steve Perrin, our President and Chief Scientific Officer, who will be available to answer questions after my comments.
We started this year with a new name, Eledon Pharmaceuticals, to highlight the new direction that our company is pursuing. Eledon was formed last September through the concurrent acquisition by Novus Therapeutics of Anelixis Therapeutics, a private immunology-focused company, and the completion of an over $108 million private placement financing to provide our company with sufficient capital to complete up to four Phase
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |